Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F Evans

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Clinical Pharmacology and Therapeutics|February 26, 2010
Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP)G Bain, C D King, M Rewolinski, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 17, 2010
Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonistJ S Swaney, C Chapman, L D Correa, et al.
The Journal of Biological Chemistry|June 14, 2000
Characterization of the human cysteinyl leukotriene 2 receptorC E Heise, B F O'Dowd, D J Figueroa, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
Nature|July 3, 1999
Characterization of the human cysteinyl leukotriene CysLT1 receptorK R Lynch, G P O'Neill, Q Liu, et al.
Nature|July 14, 2000
Identification of receptors for neuromedin U and its role in feedingA D Howard, R Wang, S S Pong, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Clinical Pharmacology and Therapeutics|February 26, 2010
Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP)G Bain, C D King, M Rewolinski, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 17, 2010
Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonistJ S Swaney, C Chapman, L D Correa, et al.
The Journal of Biological Chemistry|June 14, 2000
Characterization of the human cysteinyl leukotriene 2 receptorC E Heise, B F O'Dowd, D J Figueroa, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
Nature|July 3, 1999
Characterization of the human cysteinyl leukotriene CysLT1 receptorK R Lynch, G P O'Neill, Q Liu, et al.
Nature|July 14, 2000
Identification of receptors for neuromedin U and its role in feedingA D Howard, R Wang, S S Pong, et al.
Pageof 8